



(19) **RU** <sup>(11)</sup> **2 134 589** <sup>(13)</sup> **C1**  
(51) Int. Cl.<sup>6</sup> **A 61 K 38/17, 31/71, 35/54**

RUSSIAN AGENCY  
FOR PATENTS AND TRADEMARKS

(12) **ABSTRACT OF INVENTION**

(21), (22) Application: 98122795/14, 22.12.1998  
(24) Effective date for property rights: 22.12.1998  
(46) Date of publication: 20.08.1999  
(98) Mail address:  
123557, Moskva, Malaja Gruzinskaja ul.,  
d.37, kv.77, Fljaster G.A.

(71) Applicant:  
Zubov Dmitrij L'vovich,  
Tatulov Ehduard Borisovich,  
Dudich Elena Ivanovna,  
Dudich Igor' Vjacheslavovich,  
Semenkova Lidija Nikolaevna  
(72) Inventor: Zubov D.L.,  
Tatulov Eh.B., Dudich E.I., Dudich  
I.V., Semenkova L.N.  
(73) Proprietor:  
Zubov Dmitrij L'vovich,  
Tatulov Ehduard Borisovich,  
Dudich Elena Ivanovna,  
Dudich Igor' Vjacheslavovich,  
Semenkova Lidija Nikolaevna

(54) **METHOD OF TREATMENT OF PATIENTS WITH PRIMARY LIVER CANCER AND SET FOR TREATMENT OF PATIENTS WITH PRIMARY LIVER CANCER**

(57) Abstract:

FIELD: medicine, oncology. SUBSTANCE: method of treatment of patients with primary liver cancer involves firstly administration of alpha-fetoprotein in physiological solution in hepatic artery followed by administration of an anticancer substance preliminary dissolved in 96% ethyl alcohol where lipiodol ultrafluid is added additionally. An antitumor substance is doxorubicin at the dose 30-40 mg dissolved in 1 ml of 96% ethyl alcohol in 10 ml lipiodol ultrafluid and alpha-fetoprotein is administrated at the dose 2 mg/10 ml of

physiological solution. The set for treatment of patients with primary liver cancer has an antitumor agent, 96% ethyl alcohol, lipiodol ultrafluid, alpha-fetoprotein, sterile physiological solution (15 ml in ampoule) where doxorubicin is added as an antitumor agent at amount 30-40 mg in 3-4 flasks (volume is 10 ml), sterile lipiodol ultrafluid (5 ml in 2 ampoules), sterile human preparation of lyophilized alpha-fetoprotein at amount 2 mg in flasks (volume is 1 ml in ampoule). EFFECT: enhanced effectiveness of method, decreased toxicity. 3 cl, 1 tbl, 3 ex

RU 2 134 589 C1

RU 2 134 589 C1



RUSSIAN AGENCY  
FOR PATENTS AND TRADEMARKS

(19) **RU** (11) **2 179 452** (13) **C1**  
(51) Int. Cl. <sup>7</sup> **A 61 K 38/17, A 61 P 35/00**

(12) **ABSTRACT OF INVENTION**

(21), (22) Application: 2000116417/14, 22.06.2000

(24) Effective date for property rights: 22.06.2000

(46) Date of publication: 20.02.2002

(98) Mail address:  
630117, g.Novosibirsk, ul.Vjazemskaja, 2,  
kv.91, L.Ja.Kuchumovoj

(71) Applicant:  
Pak Vladimir Nikolaevich

(72) Inventor: Pak V.N.,  
Pak N.A., Reshetnikov S.S., Nikonov  
S.D., Ogirenko A.P.

(73) Proprietor:  
Pak Vladimir Nikolaevich

(54) **METHOD TO TREAT MALIGNANT NEOPLASMS AND COMBINED PREPARATION OF ANTITUMOR ACTION  
TO PERFORM THE METHOD**

(57) Abstract:

FIELD: medicine, oncology. SUBSTANCE: it is suggested as dependent upon character and severity of a disease to inject parenterally a combined AFP-containing preparation at 0.07-0.15 mg, polyenic antibiotic, predominantly amphoterycin B or nistatine at 4.2-7.0 mg and a filler, once daily at 3-d-long interval, at therapy course consisted of 10 infusion-drop injections. Combined preparation of antitumor action

contains the following components, mg: AFP 0.07-0.15, polyenic antibiotic 4.2-7.0, filler 3.5-5.0. As a filler it is predominantly used polysaccharide of rheopolyglukin, polyglukin or sugar group, for example, glucose. EFFECT: decreased doses of injected medicinal preparations and therapy cost, increased efficiency of antitumor action, decreased quantity of components, simplified production and prolonged storage period. 4 cl

RU 2 179 452 C1

RU 2 179 452 C1